Aptose Biosciences (APTO) PT Raised to $9 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts APTO Hot Sheet
Price: $1.71 --0%
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Join SI Premium – FREE
RBC Capital analyst Gregory Renza raised the price target on Aptose Biosciences (NASDAQ: APTO) to $9.00 (from $8.00) while maintaining a Outperform rating.
You May Also Be Interested In
- AMC Entertainment (AMC) PT Raised to $4 at B.Riley
- Quintiles (Q) PT Lowered to $183 at BMO Capital
- Algonquin Power & Utilities Corp. (AQN:CN) (AQN) PT Raised to Cdn$0.85 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
